Form 4: Cue Biopharma CFO Kerri-Ann Millar Reports Stock Option Grant

Kerri-Ann Millar, CFO of Cue Biopharma, reports the acquisition of stock options in a recent SEC Form 4 filing.

Summary

• Kerri-Ann Millar, the Chief Financial Officer of Cue Biopharma, Inc., filed a Form 4 with the SEC.
• The filing pertains to changes in beneficial ownership of securities.
• On June 5, 2024, Millar acquired stock options to purchase 60,000 shares of Cue Biopharma's common stock at an exercise price of $1.65 per share.
• The options vest in eight equal semi-annual installments starting on December 5, 2024, and expire on June 4, 2034.
• Following the transaction, Millar directly owns 60,000 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The document is a standard SEC filing, indicating a neutral sentiment. The grant of stock options is generally a positive sign, aligning management interests with shareholders, but it's a routine occurrence.

Positives

• The acquisition of stock options by the CFO could align her interests with those of the shareholders, incentivizing her to improve the company's performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This allows investors to monitor the buying and selling activity of individuals with access to non-public information.

Stakeholder Impact

• The grant of stock options could potentially align the CFO's interests more closely with those of the shareholders.

Key Dates